Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Looking to the future of patient empowerment

By Max Noble

- PMLiVE

Gilead completes acquisition of MiroBio in $405m cash deal

The UK biotech is a spin-out of Oxford University focused on research into autoimmune diseases

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

BeiGene’s Brukinsa gets green light from NICE as Waldenström’s macroglobulinemia treatment

The condition occurs in less than 2% of patients with non-Hodgkin lymphomas

- PMLiVE

Tiziana’s Foralumab shows promise in second patient with secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

bluebird bio’s Skysona approved by FDA to treat cerebral adrenoleukodystrophy

The gene therapy was shown to slow the progression of neurologic dysfunction

How long should my healthcare video be?

How long should my healthcare video be?

This week, Tim took a deeper look at a question we are asked almost daily; how long should my healthcare video be?

The Good Ideas Group

My Lucid journey from PMW to Head of Medical

Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced...

Lucid Group Communications Limited

- PMLiVE

Creating patient support programmes that help patients thrive

By Laura Meade

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives CHMP recommendation for prevention of RSV disease in infants

Beyfortus reduced the incidence of medically attended lower respiratory tract infections caused by RSV

- PMLiVE

Otsuka and Aurinia’s Lupkynis granted EC approval as active lupus nephritis treatment

The treatment is for use in combination with mycophenolate mofetil

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links